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BACKGROUND: There is a lack of data on factors that are related to clinically relevant bleeding after ticagrelor treatment. We 
investigated the clinical and procedural factors related to major bleeding in patients with acute coronary syndrome treated with 
ticagrelor after coronary stent implantation.
METHODS AND RESULTS: From the TICO (Ticagrelor Monotherapy After 3 Months in Patients Treated With New Generation 
Sirolimus- Eluting Stent for Acute Coronary Syndrome) randomized trial, a total of 2660 patients were included for the present 
study. Patients with major bleeding, defined by TIMI (Thrombolysis in Myocardial Infarction) major or Bleeding Academic 
Research Consortium type 3 or 5, were compared with those without major bleeding. On the basis of multivariable and re-
ceiver operating characteristic curve analyses, weight ≤65 kg, hemoglobin ≤12 g/dL, and estimated glomerular filtration rate 
<60 mL/min per 1.73 m2 were associated with an increased risk of major bleeding. In contrast, 3- month aspirin therapy with 
continued ticagrelor (versus 12- month aspirin and ticagrelor) was associated with a decreased risk of major bleeding. The 
lower risk of a net adverse clinical event (a composite of TIMI major bleeding and major adverse cardiac and cerebrovascular 
events) in patients treated with 3- month aspirin therapy reported from the TICO trial remained valid in patients with any of these 
risk factors (hazard ratio, 0.59; 95% CI, 0.39– 0.90; Pinteraction=0.74).
CONCLUSIONS: Low body weight, anemia, and chronic kidney disease were risk factors for major bleeding after ticagrelor 
therapy. Early aspirin discontinuation had a net clinical benefit among patients with a bleeding risk.
REGISTRATION: URL: https://www.clini caltr ials.gov/. Unique Identifier: NCT02494895.
Key Words: acute coronary syndrome ■ antiplatelet therapy ■ drug- eluting stent
It is reasonable to use ticagrelor in preference to clopi-dogrel for maintenance P2Y12 inhibitor therapy in pa-tients with acute coronary syndrome (ACS) treated 
with dual antiplatelet therapy (DAPT) after coronary stent 
implantation.1,2 Although ticagrelor reduces ischemic 
events in these patients, bleeding is a major treatment- 
related concern. In the PLATO (Platelet Inhibition and 
Patient Outcomes) trial,3 ticagrelor (compared with clopi-
dogrel) resulted in fewer ischemic complications but led 
to more frequent major bleeding events not related to 
coronary artery bypass grafting. Results from a recent 
network meta- analysis confirmed increased bleeding 
with ticagrelor treatment compared with clopidogrel.4 
Given the beneficial effects of this potent P2Y12 inhibitor 
on ischemia, it is clinically essential to assess the risk of 
bleeding with ticagrelor therapy.
On the basis of the above, we sought to evaluate 
the clinical and procedural factors related to clinically 
Correspondence to: Seung- Yul Lee, MD, Department of Cardiovascular Medicine, Regional Cardiocerebrovascular Center, Wonkwang University Hospital, 
895 Muwang- ro, Iksan, 54538, Korea. E- mail: seungyul79@gmail.com and Jae Young Cho, MD, Department of Cardiovascular Medicine, Regional 
Cardiocerebrovascular Center, Wonkwang University Hospital, 895 Muwang- ro, Iksan, 54538, Korea. E- mail: librato46@gmail.com 
Supplementary Material for this article is available at https://www.ahajo urnals.org/doi/suppl/ 10.1161/JAHA.120.019630
For Sources of Funding and Disclosures, see page 9.
© 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative 
Commons Attribution- NonCommercial- NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use 
is non- commercial and no modifications or adaptations are made. 
JAHA is available at: www.ahajournals.org/journal/jaha
J Am Heart Assoc. 2021;10:e019630. DOI: 10.1161/JAHA.120.019630 2
Cho et al Bleeding Factors for Ticagrelor Therapy
relevant bleeding in patients with ACS treated with ti-
cagrelor after coronary stent implantation.
METHODS
The data that support the findings of this study are 
available from the corresponding author on reason-
able request.
Study Population
From the TICO (Ticagrelor Monotherapy After 3 
Months in Patients Treated With a New Generation 
Sirolimus- Eluting Stent for Acute Coronary Syndrome) 
trial,5 a total of 2660 patients with ACS treated with 
ticagrelor were included for the present study. Briefly, 
the TICO trial was an investigator- initiated, multicenter, 
randomized, unblinded trial conducted at 38 cent-
ers in Korea. It tested whether switching to ticagrelor 
monotherapy after 3 months of DAPT (3- month aspi-
rin therapy) would reduce net adverse clinical events 
compared with a ticagrelor- based 12- month DAPT 
regimen (12- month aspirin therapy) among patients 
with ACS treated with drug- eluting stents. Patients 
who underwent successful percutaneous coronary 
intervention (PCI) with ultrathin bioresorbable polymer 
sirolimus- eluting stents (Orsiro; Biotronik, Germany) 
for ACS (ST- segment– elevation myocardial infarction, 
non– ST- segment– elevation myocardial infarction, or 
unstable angina) were eligible for enrollment (Table 
S1). The TICO trial excluded patients at an increased 
risk of bleeding attributable to following conditions: 
any hemorrhagic stroke, ischemic stroke or impair-
ment of central nervous system within a year, internal 
bleeding within 6 weeks, hemoglobin ≤8 g/dL, plate-
let count <100×103/mL, major surgery or traumatic 
injury resulting in any impairment of physical activity 
within 3 weeks, need for oral anticoagulation therapy, 
life expectancy <1  year, or moderate to severe he-
patic dysfunction (Table S1). Between August 2015 
and October 2018, a total of 3056 patients were ran-
domly assigned to ticagrelor monotherapy after a 3- 
month DAPT (n=1527) regimen or a ticagrelor- based 
12- month DAPT regimen (n=1529). Among these pa-
tients, 396 who did not receive the intervention as ran-
domized were excluded from the present study; 251 
received other P2Y12 inhibitors, 95 received unspeci-
fied aspirin therapy, and 50 received aspirin monother-
apy. Therefore, the present analyses were based on 
the per- protocol cohort in the TICO trial. The detailed 
protocol and participant schema of the TICO trial were 
previously described.5 The study was approved by an 
institutional review committee, and the subjects gave 
informed consent.
Procedures
PCI was performed according to standard techniques. 
The access sites for PCI and the size and length of 
implanted stents were determined by operators. Before 
PCI, loading doses of aspirin (300 mg) and ticagrelor 
(180 mg) were administered. After PCI, a single aspirin 
dose (100 mg per day) and 2 ticagrelor doses (90 mg 
per day) were maintained. After 3 months of DAPT, aspi-
rin was discontinued in the patients who were assigned 
to receive ticagrelor monotherapy after 3  months of 
DAPT, and aspirin use was continued in patients who 
were randomized to receive ticagrelor- based DAPT for 
12 months. The concomitant use of other antiplatelet 
agents or anticoagulants was not allowed.
Outcomes and Definitions
Major bleeding was defined according to the TIMI 
(Thrombolysis in Myocardial Infarction)6 or the Bleeding 
Academic Research Consortium (BARC) criteria.7 The 
TIMI criteria defined major bleeding as non– coronary 
artery bypass grafting– related bleeding with intracranial 
bleeding, hemorrhage with a hemoglobin decrease of 
at least 5 g/dL, or bleeding that was fatal within 7 days.6 
The major bleeding by BARC criteria was defined as type 
3 (clinical, laboratory, and/or imaging evidence of bleed-
ing with specific healthcare provider responses) or type 
5 bleeding (bleeding that directly causes death with no 
other explainable cause).7 The BARC type 3 category 
was further classified into 3a, 3b, and 3c, according 
CLINICAL PERSPECTIVE
What Is New?
• Low body weight, anemia, and chronic kidney 
disease increase major bleeding risk after tica-
grelor therapy.
What Are the Clinical Implications?
• These bleeding factors may be considered for 
adopting ticagrelor as P2Y12 inhibitor therapy 
among patients with acute coronary syndrome 
undergoing drug- eluting stent implantation.
Non- standard Abbreviations and Acronyms
BARC Bleeding Academic Research Consortium
DAPT dual antiplatelet therapy
TICO Ticagrelor Monotherapy After 3  Months 
in Patients Treated With New Generation 
Sirolimus- Eluting Stent for Acute 
Coronary Syndrome
TIMI Thrombolysis in Myocardial Infarction
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to the BARC criteria.7 On the basis of the TICO trial,5 a 
major adverse cardiac and cerebrovascular event was 
defined as a composite of death, myocardial infarction, 
stent thrombosis, stroke, and target- vessel revascu-
larization; a net adverse clinical event was defined as a 
composite of TIMI major bleeding and a major adverse 
cardiac and cerebrovascular event.
Cardiac death was defined as death attributable to 
myocardial infarction, cardiac perforation, or pericar-
dial tamponade; arrhythmia or conduction abnormal-
ity; stroke within 30 days of the procedure or related 
to the procedure; death attributable to a procedural 
complication; or any case of death in which a cardiac 
cause was not excluded by a clinical event commit-
tee.5 Myocardial infarction after hospital discharge was 
defined by ischemic symptoms, electrocardiographic 
changes, or abnormal imaging findings, combined with 
a creatine kinase myocardial band fraction above the 
upper normal limit or a troponin T or troponin I level >99th 
percentile of the upper normal limit.8 Stent thrombosis 
was defined as definite or probable stent thrombosis, 
according to the Academic Research Consortium cri-
teria.9 Stroke was defined as a fatal acute cerebrovas-
cular event, a neurological deficit lasting >24  hours, 
or an acute infarction revealed by imaging studies.10 
Target- vessel revascularization was defined as a re-
peated PCI or bypass surgery of the target vessel with 
either1: symptoms of ischemia or a positive stress test 
and an angiographic diameter stenosis of >50%; or2 an 
angiographic diameter stenosis of >70% without symp-
toms of ischemia or a positive stress test.5
Outcomes were categorized according to predefined 
criteria by an independent clinical event committee blinded 
to the treatment assignments and primary results.5
Statistical Analysis
Continuous variables are reported as mean±SD and 
were compared using the Student t test. Categorical 
variables are reported as numbers (percentages) and 
were compared using the Fisher exact test or the χ2 
test. Hazard ratios (HRs) with 95% CIs were analyzed 
by Cox regression analysis, including each participat-
ing institution as a random effect. Clinically relevant 
variables or statistically significant variables on uni-
variate analysis were entered into the multivariable 
model that assessed independent factors for TIMI 
major bleeding and BARC type 3 or 5 bleeding (Table 
S2). Given the overfitting of our model, entered vari-
ables were as follows: age, women, weight, diabetes 
mellitus, current smoker, prior stroke (only for BARC 
bleeding), hemoglobin, thrombocytopenia (platelets 
<100×103/mL) (only for BARC bleeding), chronic kidney 
disease (estimated glomerular filtration rate <60  mL/
min per 1.73 m2), transradial intervention, and 3- month 
aspirin therapy. Kaplan- Meier estimates were used 
to determine the cumulative incidences of study out-
comes at 12 months. A total of 110 and 107 patients 
were censored for TIMI major bleeding and BARC type 
3/5 bleeding, respectively, because of the follow- up 
loss before 12 months or the withdrawal of consent. In 
this case, the last information available for study was 
used for the survival analysis. The optimal cutoff values 
for bleeding- related variables were determined consid-
ering the Youden index derived from receiver operating 
characteristic curve analysis and whether it is suita-
ble for clinical use. Statistical analysis was performed 
using SAS 9.2 (SAS Institute) or MedCalc (MedCalc 
Software). All tests were 2 sided, and a P<0.05 was 
considered statistically significant.
RESULTS
Distribution of Major Bleeding
Among 2660 patients treated with ticagrelor, 54 
(2.0%) and 97 (3.6%) patients underwent TIMI major 
bleeding and BARC type 3/5 bleeding, respectively, 
within 12 months of therapy initiation. There were 39 
cases of BARC type 3a, 51 cases of BARC type 3b, 
5 cases of BARC type 3c, and 2 cases of BARC type 
5 bleeding. Coronary artery bypass grafting was not 
performed in these patients. Figure 1 represents the 
frequency of bleeding events. Within 30 days after tica-
grelor treatment, 53.7% (29/54) of TIMI major bleeding 
(Figure 1A) and 47.4% (46/97) of BARC type 3/5 events 
were recorded (Figure 1B). The periprocedural bleed-
ing occurred in 18.5% (10/54) of TIMI major bleeding 
(Figure 1A) and 20.6% (20/97) of BARC type 3/5 bleed-
ing (Figure 1B).
Risk Factors for Major Bleeding
Given the heterogeneity of bleeding definitions, pa-
tients with TIMI major bleeding were compared with 
those without; those with BARC type 3/5 bleeding 
were compared with those without.
Table  1 shows the baseline characteristics of pa-
tients with and without TIMI major bleeding. Patients 
with TIMI major bleeding were older and weighed less 
than those without. In patients with TIMI major bleed-
ing, the frequencies of women and diabetes mellitus 
were higher, and the levels of hemoglobin and esti-
mated glomerular filtration rate were lower. Transradial 
intervention and 3- month aspirin therapy were less 
frequently administered in patients with TIMI major 
bleeding. Table  2 shows the baseline characteristics 
of patients with and without BARC type 3/5 bleeding. 
Differences among variables were similar to those 
from TIMI major bleeding, except that the frequency 
of current smoker was less in patients with BARC type 
3/5 bleeding. Table 3 demonstrates independent cor-
relates of major bleeding after ticagrelor therapy. The 
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weight was associated with an increased risk of BARC 
type 3/5 bleeding. The hemoglobin and estimated glo-
merular filtration rate <60 mL/min per 1.73 m2 (chronic 
kidney disease) were associated with an increased 
risk of both TIMI major bleeding and BARC type 3/5 
bleeding.
On the basis of the receiver operating characteristic 
curve analyses (Figure S1), ≤65 kg (low body weight) 
was the optimal cutoff value for body weight to predict 
both TIMI major bleeding and BARC type 3/5 bleeding 
(area under the receiver operating characteristic curve 
[95% CI]: TIMI major bleeding, 0.65 [0.63– 0.67]; BARC 
type 3/5 bleeding, 0.66 [0.64– 0.68]). With this thresh-
old, the diagnostic sensitivity and specificity were 
66.7% and 60.0%, respectively, for TIMI major bleed-
ing, and 65.6% and 60.4%, respectively, for BARC type 
3/5 bleeding. The optimal cutoff value for hemoglobin 
was ≤12 g/dL (anemia) (area under the receiver operat-
ing characteristic curve [95% CI]: TIMI major bleeding, 
0.70 [0.68– 0.71]; BARC type 3/5 bleeding, 0.65 [0.64– 
0.67]). With this threshold, the diagnostic sensitivity 
and specificity were 35.2% and 91.3%, respectively, 
for TIMI major bleeding, and 30.9% and 91.5%, re-
spectively, for BARC type 3/5 bleeding.
The HR (95% CI) of risk factors for TIMI major 
bleeding and BARC type3/5 were as follows: low body 
weight, 3.08 (1.74– 5.43) and 2.96 (1.94– 4.53), respec-
tively; anemia, 5.72 (3.26– 10.04) and 4.91 (3.18– 7.58), 
respectively; and chronic kidney disease, 3.68 (2.14– 
6.34) and 2.79 (1.84– 4.23), respectively. TIMI major 
bleeding (Figure  2A) and BARC type 3/5 bleeding 
(Figure 2B) occurred more frequently in proportion to 
the burden of risk factors.
Effects of Early Aspirin Discontinuation 
and Transradial Intervention
The 3- month aspirin therapy plus ticagrelor regimen 
was associated with a decreased risk of major bleeding, 
compared with the 12- month aspirin plus ticagrelor 
regimen (Table  3). Baseline characteristics were not 
different between patients with 3- and 12- month as-
pirin therapies (Table S3).5 Table 4 summarizes clinical 
outcomes at 12 months. The 3- month aspirin therapy 
resulted in a reduction of net adverse clinical events 
compared with the 12- month aspirin therapy.5 This ef-
fect of early aspirin discontinuation was consistent in 
patients with a risk of major bleeding (Table 5).
Transradial access for PCI showed a tendency to be 
associated with a decreased risk of major bleeding, com-
pared with a transfemoral intervention (Table 3). Although 
a lower risk of net adverse clinical events was identified in 
patients administered a transradial intervention (Table 4 
and Table 5), baseline characteristics were different be-
tween patients with transradial and transfemoral inter-
ventions (Table S4). However, the net benefit was still 
valid even after multivariable adjustments for age, sex, 
current smoker status, clinical presentation of myocar-
dial infarction, chronic kidney disease, and multivessel 
disease (HR [95% CI], 0.66 [0.45– 0.98]; P=0.0385).
Figure 3A (early aspirin discontinuation) and 
Figure 3B (transradial intervention) represent time- to- 
event curves for net adverse clinical events in patients 
at risk of major bleeding.
DISCUSSION
The main findings of this post hoc analysis are as 
follows: (1) 50% of major bleeding events occurred 
within 30 days after ticagrelor treatment; (2) low body 
weight, anemia, and chronic kidney disease were 
risk factors for major bleeding; (3) net clinical ben-
efits of early aspirin discontinuation, as reported by 
the TICO trial, were still valid in patients with any of 
the major bleeding risk factors; and (4) transradial in-
tervention, compared with transfemoral intervention, 
showed potential benefits on reducing major bleed-
ing and improving net outcomes.
Figure 1. Distribution of major bleeding events.
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The PRECISE- DAPT (PREdicting bleeding 
Complications In patients undergoing Stent implan-
tation and subsEquent Dual Anti Platelet Therapy) 
score was designed to evaluate the benefits and risks 
of different DAPT durations and may be considered 
at the time of PCI.1,2 However, the score was based 
on pooled analysis of 8 randomized trials that were 
treated with DAPT, largely consisting of aspirin and 
clopidogrel.11 Although the PRECISE- DAPT score 









Age, y 65.2±9.0 60.5±10.8 0.0013
Women 19 (35.2) 506 (19.4) 0.0040
Weight, kg 63.2±10.0 69.0±11.8 0.0004
Comorbid conditions
Hypertension 30 (55.6) 1289 (49.5) 0.3754
Diabetes mellitus 24 (44.4) 687 (26.4) 0.0030
Current smoker 17 (31.5) 1009 (38.7) 0.2795
Dyslipidemia 28 (51.9) 1576 (60.5) 0.1998
Prior percutaneous coronary 
intervention
6 (11.1) 206 (7.9) 0.4397
Prior stroke 3 (5.6) 105 (4.0) 0.4809
Clinical presentation
Unstable angina 17 (31.5) 762 (29.2) 0.5277
Non– ST- segment– elevation 
myocardial infarction
21 (38.9) 880 (33.8)
ST- segment– elevation 
myocardial infarction
16 (29.6) 964 (37.0)
Laboratory findings at admission
White blood count, ×103/mL 10.1±4.5 9.4±3.5 0.2127
Hemoglobin, g/dL 13.0±2.0 14.3±1.7 <0.0001
Platelets, ×103/mL 268±146 242±64 0.1945
Estimated glomerular filtration 
rate, mL/min per 1.73 m2
61.2±29.7 77.6±23.3 0.0002
<60 mL/min per 1.73 m2 24 (44.4) 503 (19.3) <0.0001
Antithrombotic drug before intervention
Unfractionated heparin 33 (61.1) 1627 (62.4) 0.8427
Low– molecular- weight 
heparin
6 (11.1) 235 (9.0) 0.6283
Glycoprotein IIb/IIIa inhibitors 2 (3.7) 177 (6.8) 0.5806
Multivessel coronary artery 
disease
32 (59.3) 1445 (55.4) 0.5770
Percutaneous coronary intervention
Emergent intervention 15 (27.8) 923 (35.4) 0.2448
Transradial approach 18 (33.3) 1461 (56.1) 0.0009
Multilesion intervention 11 (20.4) 516 (19.8) 0.9172
Multivessel intervention 11 (20.4) 433 (16.6) 0.4639
Treated lesions per patient 1.2±0.5 1.2±0.5 0.8810
Total No. of stents per patient 1.3±0.6 1.4±0.7 0.7376
Total stent length per patient, 
mm
34±16 35±20 0.6431
3- mo Aspirin therapy 19 (35.2) 1320 (50.7) 0.0244
Data are presented as mean±SD or number (percentage). TIMI indicates 
Thrombolysis in Myocardial Infarction.
Table 2. Baseline Characteristics, Grouped by BARC 
Criteria
Characteristic







Age, y 64.5±9.7 60.4±10.8 0.0002
Women 31 (32.0) 494 (19.3) 0.0021
Weight, kg 63.1±9.4 69.1±11.9 <0.0001
Comorbid conditions
Hypertension 54 (55.7) 1265 (49.4) 0.2221
Diabetes mellitus 36 (37.1) 675 (26.3) 0.0186
Current smoker 27 (27.8) 999 (39.0) 0.0269
Dyslipidemia 51 (52.6) 1553 (60.6) 0.1132
Prior percutaneous coronary 
intervention
7 (7.2) 205 (8.0) 0.7801
Prior stroke 4 (4.1) 104 (4.1) 1.0000
Clinical presentation
Unstable angina 28 (28.9) 751 (29.3) 0.8874
Non– ST- segment– elevation 
myocardial infarction
35 (36.1) 866 (33.8)
ST- segment– elevation 
myocardial infarction
34 (35.1) 946 (36.9)
Laboratory findings at admission
White blood count, ×103/mL 10.4±5.3 9.3±3.5 0.0668
Hemoglobin, g/dL 13.3±2.1 14.3±1.7 <0.0001
Platelets, ×103/mL 260±117 241±64 0.1150
Estimated glomerular filtration 
rate, mL/min per 1.73 m2
64.5±25.4 77.7±23.3 <0.0001
<60 mL/min per 1.73 m2 37 (38.1) 490 (19.1) <0.0001
Antithrombotic drug before intervention
Unfractionated heparin 61 (62.9) 1599 (62.4) 0.9207
Low– molecular- weight heparin 8 (8.2) 233 (9.1) 0.7763
Glycoprotein IIb/IIIa inhibitors 7 (7.2) 172 (6.7) 0.8453
Multivessel coronary artery 
disease
56 (57.7) 1421 (55.4) 0.6561
Percutaneous coronary intervention
Emergent intervention 34 (35.1) 904 (35.3) 0.9646
Transradial approach 39 (40.2) 1440 (56.2) 0.0019
Multilesion intervention 17 (17.5) 510 (19.9) 0.5649
Multivessel intervention 17 (17.5) 427 (16.7) 0.8224
Treated lesions per patient 1.2±0.4 1.2±0.5 0.4658
Total No. of stents per patient 1.3±0.6 1.4±0.7 0.6136
Total stent length per patient, 
mm
34±19 35±20 0.7343
3- mo Aspirin therapy 35 (38.0) 1246 (50.0) 0.0251
Data are presented as mean±SD or number (percentage). BARC indicates 
Bleeding Academic Research Consortium.
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was validated in the PLATO trial population, a c- index 
for out- of- hospital TIMI major or minor bleeding was 
modest (0.70 in the PLATO trial validation cohort and 
0.66 in the BernPCI registry validation cohort).11 In 
addition, risk factors related to bleeding were not 
consistent across studies. In the PLATO trial, in-
creasing age, decreasing creatinine clearance, low 
admission hemoglobin, female sex, prior gastroin-
testinal bleeding, glycoprotein IIb/IIIa inhibitor use, 
and randomization to ticagrelor were associated with 
non– coronary artery bypass grafting– related major 
bleeding,12 whereas age, creatinine clearance, he-
moglobin, white blood cell count, and previous spon-
taneous bleeding were predictors for out- of- hospital 
bleeding in the PRECISE- DAPT score.11 Given the 
above limitations and uncertainties, data on specific 
bleeding factors directly linked to ticagrelor therapy 
provide addition information to improve clinical out-
comes in patients with ACS undergoing PCI.
Age and female sex were statistically attenuated 
in the present multivariable analyses, whereas low 
body weight, anemia, and chronic kidney disease 
were significant correlates of major bleeding, even 
after the adjustments. In contrast to clopidogrel and 
prasugrel, ticagrelor does not require metabolic acti-
vation and binds rapidly and reversibly to the P2Y12 
receptor.13 CYP2C19 and ABCB1 genotypes do not 
appear to influence ticagrelor pharmacodynamics.13 
The effects of age and sex on the pharmacokinet-
ics of ticagrelor are modest, and do not require dose 
adjustment.13 The other points to be considered are 
differences in the study population. In the PLATO 
trial, the median age and body weight were about 
62  years and 80  kg, respectively, whereas those 
were 61 years and 69 kg, respectively, in the pres-
ent study. Thus, in the present study, fewer elderly 
patients were included, but patients with low body 
weight were more represented. Because the TICO 
trial enrolled patients from Korea, the racial difference 




Ratio 95% CI P Value
TIMI major bleeding
Age 1.00 0.97– 1.03 0.9203
Women 1.07 0.55– 2.07 0.8463
Weight per 1- kg increase 0.97 0.94– 1.00 0.0675
Diabetes mellitus 1.38 0.77– 2.47 0.2817
Hemoglobin per 1- g/dL increase 0.79 0.67– 0.93 0.0054
Chronic kidney disease (estimated 
glomerular filtration rate <60 mL/
min per 1.73 m2)
2.22 1.21– 4.09 0.0106
Transradial intervention 0.55 0.30– 1.02 0.0560
3- mo Aspirin therapy 0.56 0.32– 0.98 0.0428
Bleeding Academic Research Consortium type 3 or 5 bleeding
Age 1.00 0.98– 1.03 0.9473
Women 0.89 0.53– 1.50 0.6561
Weight per 1- kg increase 0.96 0.94– 0.99 0.0021
Diabetes mellitus 1.17 0.75– 1.83 0.4983
Current smoker 0.80 0.49– 1.32 0.3775
Prior stroke 0.69 0.25– 1.92 0.4817
Hemoglobin per 1- g/dL increase 0.82 0.72– 0.94 0.0036
Thrombocytopenia (platelets 
<100×103/mL)
1.10 0.15– 8.23 0.9297
Chronic kidney disease (estimated 
glomerular filtration rate <60 mL/
min per 1.73 m2)
2.02 1.27– 3.20 0.0029
Transradial intervention 0.67 0.42– 1.06 0.0887
3- mo Aspirin therapy 0.66 0.44– 0.99 0.0486
TIMI indicates Thrombolysis in Myocardial Infarction.
Figure 2. Event rates for major bleeding, at 12- month follow- up.
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may affect the present results. A recent randomized 
clinical trial conducted in Korean patients with ACS 
resulted in the higher incidence of clinically significant 
bleeding in patients treated with ticagrelor compared 
with clopidogrel.14 However, the subgroup analyses 
from the PLATO trial or the pharmacokinetic findings 
of ticagrelor were not different according to the eth-
nicity.12,13 The low body weight may strengthen the 
direct antiplatelet effects of ticagrelor, presumably 
by increasing plasma concentrations of ticagrelor 
and AR- C124910XX (active metabolite of ticagrelor). 
Although low body weight was one of the risk factors 
for bleeding, as per the 2016 American College of 
Cardiology/American Heart Association guidelines,1 it 
was absent in the criteria developed by the Academic 
Research Consortium for high bleeding risk.15 The 
major and minor criteria for high bleeding risk at 
the time of PCI, defined by the Academic Research 
Consortium, included anticipated use of long- term 
oral anticoagulation, chronic kidney disease, ane-
mia, spontaneous bleeding requiring hospitalization 
or transfusion, thrombocytopenia, chronic bleeding 
diathesis, liver cirrhosis with portal hypertension, ac-
tive malignancy, intracranial hemorrhage, ischemic 
stroke, nondeferrable major surgery on DAPT, recent 
major surgery or trauma, age ≥75  years, and long- 
term use of oral nonsteroidal anti- inflammatory drugs 
or steroids.15
Previously, the TWILIGHT (Ticagrelor With Aspirin 
or Alone in High- Risk Patients After Coronary 
Intervention) trial, including high- risk patients who 
underwent PCI, revealed that ticagrelor mono-
therapy was associated with a lower incidence of 
clinically relevant bleeding than was ticagrelor plus 
aspirin, without an increase in risk of death, myocar-
dial infarction, or stroke.16 Thus, the present study 
is in line with the results from the TWILIGHT trial 
and confirms the effectiveness of early termination 
of DAPT among patients with ACS with high bleed-
ing risk after coronary stent implantation. However, 
it is not yet clear whether aspirin or ticagrelor may 
be discontinued in those patients. Although dis-
continuation of P2Y12 inhibitor therapy is currently 
recommended in patients with ACS with stent im-
plantation who are at high risk of bleeding,1,2 it has 
been associated with an increased risk of ischemic 
events in patients with ACS undergoing PCI.17,18 In 
addition, results from the landmark analysis of the 
Table 4. Clinical Outcomes at 12 Months
Outcome
3- mo Aspirin 
(n=1339)
12- mo Aspirin 
(n=1321) Hazard Ratio 95% CI P Value
TIMI major bleeding 19 (1.4) 35 (2.7) 0.53 0.30– 0.92 0.0243
BARC type 3 or 5 bleeding 38 (2.9) 59 (4.5) 0.62 0.41– 0.93 0.0218
Major adverse cardiac and cerebrovascular event 29 (2.2) 46 (3.5) 0.62 0.39– 0.99 0.0450
Death 16 (1.2) 23 (1.8) 0.69 0.36– 1.30 0.2520
Cardiac 7 12
Noncardiac 9 11
Myocardial infarction 3 (0.2) 9 (0.7) 0.33 0.09– 1.22 0.0956
Stent thrombosis 5 (0.4) 4 (0.3) 1.24 0.33– 4.60 0.7526
Stroke 7 (0.5) 9 (0.7) 0.77 0.29– 2.06 0.5962
Target- vessel revascularization 4 (0.3) 9 (0.7) 0.44 0.14– 1.42 0.1704





(n=1181) Hazard Ratio 95% CI P Value
TIMI major bleeding 18 (1.2) 36 (3.1) 0.48 0.27– 0.88 0.0168
BARC type 3 or 5 bleeding 39 (2.7) 58 (5.0) 0.60 0.39– 0.94 0.0264
Major adverse cardiac and cerebrovascular event 37 (2.5) 38 (3.3) 0.78 0.49– 1.22 0.2626
Death 22 (1.5) 17 (1.5) 0.99 0.52– 1.88 0.9714
Cardiac 12 7
Noncardiac 10 10
Myocardial infarction 6 (0.4) 6 (0.5) 0.80 0.26– 2.47 0.6934
Stent thrombosis 6 (0.4) 3 (0.3) 1.59 0.40– 6.37 0.5105
Stroke 8 (0.5) 8 (0.7) 0.79 0.30– 2.12 0.6397
Target- vessel revascularization 4 (0.3) 9 (0.8) 0.35 0.11– 1.15 0.0840
Net adverse clinical event 52 (3.6) 69 (5.9) 0.62 0.43– 0.90 0.0120
Data are given as number (percentage), unless otherwise indicated. Percentages are Kaplan- Meier estimates at day 365. BARC indicates Bleeding Academic 
Research Consortium; and TIMI, Thrombolysis in Myocardial Infarction.
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GLOBAL LEADERS trial (clinical study comparing 
2 forms of antiplatelet therapy after stent implan-
tation) indicate that ischemic events tended to be 
lower with ticagrelor monotherapy (versus aspirin 
monotherapy), without an increase of BARC type 
3/5 bleeding.19 Accordingly, ticagrelor monotherapy 
with early aspirin discontinuation may be considered 
among patients with ACS with high bleeding risk. 
Furthermore, given the high incidence of clinically 
relevant bleeding within 1 month after PCI in the 
present study, and the efficacy and safety of P2Y12 
inhibitor monotherapy, as per previous randomized 
clinical trials,5,16,19– 21 aspirin- free PCI or ticagre-
lor monotherapy immediately after PCI may further 
improve clinical outcomes; these aspects need to be 
investigated by future studies. Promisingly, a recent 
pilot study demonstrated the feasibility and safety 
of aspirin- free prasugrel monotherapy following suc-
cessful everolimus- eluting stent implantation in se-
lected low- risk patients with stable coronary artery 
disease.22 In patients with ACS undergoing invasive 
management, previous studies confirmed that radial 
compared with femoral access reduced net adverse 
clinical events, through a reduction in major bleeding 
and all- cause mortality.23,24 In agreement with these 
studies, the present analyses suggest that this net 
benefit may be still valid among patients with high 
bleeding risk for ticagrelor therapy.
Table 5. Clinical Outcomes, Grouped by the Presence of Major Bleeding Risk (Low Body Weight, Anemia, or Chronic 
Kidney Disease)
Outcome
Presence of Major Bleeding Risk Absence of Major Bleeding Risk Pinteraction
3- mo Aspirin  
(n=682)
12- mo Aspirin  
(n=694)
Hazard Ratio  
(95% CI)
3- mo Aspirin  
(n=629)
12- mo Aspirin  
(n=606)
Hazard Ratio  
(95% CI)
TIMI major bleeding 17 (2.5) 28 (4.1) 0.65 (0.35– 1.19) 2 (0.3) 7 (1.2) 0.28 (0.06– 1.32) 0.2868
BARC type 3/5 bleeding 31 (4.6) 47 (6.9) 0.69 (0.44– 1.08) 7 (1.1) 11 (1.8) 0.61 (0.24– 1.58) 0.7603
MACCE 18 (2.7) 37 (5.4) 0.49 (0.28– 0.87)* 9 (1.5) 9 (1.5) 0.97 (0.38– 2.43) 0.2231












Hazard ratio  
(95% CI) Pinteraction
TIMI major bleeding 15 (2.0) 30 (4.9) 0.54 (0.28– 1.05) 3 (0.4) 6 (1.1) 0.38 (0.10– 1.52) 0.9311
BARC type 3/5 bleeding 30 (4.1) 48 (7.8) 0.59 
(0.36– 0.97)*
9 (1.3) 9 (1.7) 0.76 (0.30– 1.91) 0.4505
MACCE 25 (3.4) 30 (4.9) 0.69 (0.41– 1.18) 11 (1.6) 7 (1.3) 1.20 (0.47– 3.09) 0.3228
NACE 38 (5.1) 55 (8.9) 0.60 
(0.39– 0.92)*
13 (1.9) 13 (2.5) 0.76 (0.35– 1.64) 0.4950
Data are given as number (percentage), unless otherwise indicated. Percentages are Kaplan- Meier estimates at day 365. BARC indicates Bleeding Academic 
Research Consortium; MACCE, major adverse cardiac and cerebrovascular event; NACE, net adverse clinical event; and TIMI, Thrombolysis in Myocardial 
Infarction.
*P<0.05.
Figure 3. Time- to- event curves for net adverse clinical event in patients with risk of major bleeding.
Hazard ratio (95% CI) was noted. A, Early aspirin discontinuation. B, Transradial intervention.
A B



































0.60 (0.39 – 0.92), P = 0.0195
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By interaction analyses in the present study, the 
treatment effects with early aspirin discontinuation 
and transradial access were consistent regardless of 
the presence of major bleeding risk, thus suggesting 
the possibility of these strategies to all patients with 
ACS undergoing PCI. However, this approach should 
be cautious given that current evidence has supported 
the extended use of DAPT in patients at low bleeding 
risk by reducing ischemic events without an increase 
of bleeding complications.1,2,25 In addition, the radial 
or femoral access for PCI should be determined, tak-
ing into account patients’ characteristics, clinical sit-
uations, and lesional complexities, as well as the risk 
of bleeding. Therefore, a dedicated clinical trial is re-
quired to figure out the clinical usefulness of the pres-
ent findings.
Study Limitations
First, the present study should be interpreted consid-
ering the limitations of post hoc analyses. Although 
the major bleeding was defined by TIMI major bleed-
ing or BARC type 3/5 bleeding, the weight showed 
a borderline significancy on multivariable analysis for 
TIMI major bleeding. Second, although the presence 
of prior stroke or thrombocytopenia may potentially 
increase the risk of major bleeding, it was rarely pre-
sented in the present study because the TICO trial 
excluded patients having these conditions. In addi-
tion, unmeasured variables, including peripheral ar-
tery disease, may have affected the present findings. 
Third, the effects of transradial intervention on clini-
cal outcomes should be considered as explorative. 
Fourth, bleeding factors associated with ticagrelor 
monotherapy, despite the discontinuation of aspi-
rin, are beyond our analyses, thus requiring further 
investigations. Fifth, it would be difficult to evaluate 
ticagrelor- related bleeding factors in the intention- 
to- treat cohort because not a few patients received 
other P2Y12 inhibitors or unspecified aspirin therapy. 
Finally, caution should be used to apply the results of 
this study to races other than Asians or patients re-
ceiving drug- eluting stents other than Orsiro stents.
CONCLUSIONS
Low body weight, anemia, and chronic kidney disease 
were risk factors for bleeding among patients with ACS 
treated with ticagrelor after coronary stent implanta-
tion. The strategy with early aspirin discontinuation in 
addition to ticagrelor had a net clinical benefit in pa-
tients with a bleeding risk.
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Table S1. Inclusion and exclusion criteria. 
Inclusion criteria 
1. Age 19 years old 
2. Patients who received bioresorbable polymer sirolimus-eluting stent implantation to treat acute coronary syndrome 
3. Provision of informed consent 
Exclusion criteria 
1. Age >80 years old 
2. Increased risk of bleeding due to: 
1) Any prior event of hemorrhagic stroke 
2) Ischemic stroke, dementia, or impairment of central nervous system within a year 
3) Traumatic brain injury or brain surgery within 6 months 
4) Known intracranial tumor 
5) Documented or suspected aortic dissection 
6) Internal bleeding within 6 weeks 
7) Active bleeding or bleeding diathesis 
8) Hemoglobin 8 g/dL or thrombocytopenia (platelet count <100×103/mL) 
9) Major surgery or traumatic injury resulting in any impairment of physical activity within 3 weeks 
3. Need for oral anticoagulation therapy 
4. Current or potential pregnancy 
5. Life expectancy <1 year 
6. Currently treated with strong CYP3A4 inhibitors 
7. Moderate to severe hepatic dysfunction (Child-Pugh class B or C) 




Table S2. Univariate analysis for major bleeding correlates. 
 Hazard ratio 95% CI P 
Thrombolysis in Myocardial Infarction major bleeding    
Age 1.05 1.02 – 1.08 0.0009 
Women 2.35 1.34 – 4.13 0.0028 
Weight per 1 kg increase 0.95 0.93 – 0.98 0.0002 
Hypertension 1.28 0.75 – 2.21 0.3664 
Diabetes 2.23 1.30 – 3.83 0.0036 
Current smoker 0.68 0.38 – 1.22 0.1983 
Dyslipidemia 0.75 0.43 – 1.30 0.3030 
Prior percutaneous coronary intervention 1.41 0.60 – 3.32 0.4367 
Prior stroke 1.33 0.41 – 4.29 0.6308 
Acute myocardial infarction 0.84 0.46 – 1.54 0.5779 
Leukocytosis (white blood count >11 ×103/mL) 1.56 0.89 – 2.74 0.1235 
Hemoglobin per 1 g/dL increase 0.66 0.58 – 0.76 <0.0001 
Thrombocytopenia (platelets <100 ×103/mL) 4.96 0.67 – 36.58 0.1159 
Chronic kidney disease (estimated glomerular filtration rate 
<60 mL/min/1.73 m2) 
3.67 2.13 – 6.31 <0.0001 
Unfractionated heparin 0.84 0.45 – 1.60 0.5998 
Low–molecular-weight heparin 1.51 0.58 – 3.93 0.3994 
Glycoprotein IIb/IIIa inhibitors 0.65 0.15 – 2.75 0.5529 
Emergent intervention 0.62 0.33 – 1.17 0.1384 
Transradial intervention 0.48 0.27 – 0.87 0.0157 
Multivessel intervention 1.23 0.63 – 2.40 0.5466 
3-month aspirin therapy 0.53 0.30 – 0.93 0.0255 
Bleeding Academic Research Consortium type 3/5 bleeding    
Age 1.04 1.02 – 1.06 <0.0001 
Women 2.04 1.33 – 3.13 0.0012 
Weight per 1 kg increase 0.95 0.93 – 0.97 <0.0001 
Hypertension 1.29 0.86 – 1.93 0.2251 
Diabetes 1.66 1.10 – 2.51 0.0169 
Current smoker 0.56 0.36 – 0.87 0.0109 
Dyslipidemia 0.75 0.50 – 1.13 0.1669 
Prior percutaneous coronary intervention 0.89 0.41 – 1.94 0.7752 
Prior stroke 1.01 0.37 – 2.75 0.9894 
Acute myocardial infarction 1.04 0.66 – 1.65 0.8632 
Leukocytosis (white blood count >11 ×103/mL) 1.32 0.86 – 2.02 0.2126 
Hemoglobin per 1 g/dL increase 0.71 0.64 – 0.79 <0.0001 
 
 
Thrombocytopenia (platelets <100 ×103/mL) 2.77 0.38 – 20.12 0.3146 
Chronic kidney disease (estimated glomerular filtration rate 
<60 mL/min/1.73 m2) 
2.79 1.84 – 4.23 <0.0001 
Unfractionated heparin 0.98 0.60 – 1.61 0.9341 
Low–molecular-weight heparin 0.96 0.42 – 2.17 0.9157 
Glycoprotein IIb/IIIa inhibitors 1.31 0.58 – 2.98 0.5146 
Emergent intervention 0.93 0.60 – 1.45 0.7426 
Transradial intervention 0.60 0.39 – 0.94 0.0264 
Multivessel intervention 0.99 0.58 – 1.68 0.9678 
3-month aspirin therapy 0.62 0.41 – 0.93 0.0218 
CI, confidence interval. 
 
 
Table S3. Baseline characteristics between 3-month and 12-month aspirin therapy. 





Age, years 60.3 ± 10.8 60.8 ± 10.8 0.3121 
Women 270 (20.2) 255 (19.3) 0.5771 
Weight, kg 68.9 ± 11.8 68.9 ± 11.9 0.9634 
Comorbid conditions    
Hypertension 649 (48.5) 670 (50.7) 0.2458 
Diabetes 355 (26.5) 356 (27.0) 0.7990 
Current smoker 507 (37.9) 519 (39.3) 0.4505 
Dyslipidemia 810 (60.5) 794 (60.1) 0.8384 
Prior percutaneous coronary intervention 108 (8.1) 104 (7.9) 0.8543 
Prior stroke 50 (3.7) 58 (4.4) 0.3910 
Clinical presentation   0.3035 
Unstable angina 377 (28.2) 402 (30.4)  
Non–ST-elevation myocardial infarction 470 (35.1) 431 (32.6)  
ST-elevation myocardial infarction 492 (36.7) 488 (37.0)  
Laboratory findings at admission    
White blood count, ×103/mL 9.3 ± 3.6 9.4 ± 3.5 0.5017 
Hemoglobin, g/dL 14.3 ± 1.7 14.3 ± 1.8 0.9909 
Platelets, ×103/mL 240 ± 63 244 ± 70 0.1479 
Estimated glomerular filtration rate, mL/min/1.73 m2 78.2 ± 24.5 76.3 ± 22.6 0.0362 
<60 mL/min/1.73 m2 256 (19.1) 271 (20.5) 0.3664 
Antithrombotic drug before intervention    
Unfractionated heparin 820 (61.2) 840 (63.6) 0.2112 
Low–molecular-weight heparin 112 (8.4) 129 (9.8) 0.2082 
Glycoprotein IIb/IIIa inhibitors 91 (6.8) 88 (6.7) 0.8899 
Multivessel coronary artery disease 734 (54.8) 743 (56.3) 0.4586 
Percutaneous coronary intervention    
Emergent intervention 469 (35.0) 469 (35.5) 0.7967 
Transradial intervention 734 (54.8) 745 (56.4) 0.4123 
Multilesion intervention 260 (19.4) 267 (20.2) 0.6072 
Multivessel intervention 213 (15.9) 231 (17.5) 0.2748 
Treated lesions per patient 1.2 ± 0.5 1.2 ± 0.5 0.5835 
Total No. of stents per patient 1.4 ± 0.7 1.4 ± 0.7 0.9874 
Total stent length per patient, mm 35 ± 20 35 ± 20 0.7360 
Data are presented as n ± standard deviation or n (percentage). 
 
 






Age, years 60.8 ± 10.8 60.3 ± 10.7 0.2091 
Women 314 (21.2) 211 (17.9) 0.0303 
Weight, kg 68.8 ± 12.1 69.0 ± 11.6 0.7811 
Comorbid conditions    
Hypertension 740 (50.0) 579 (49.0) 0.6056 
Diabetes 394 (26.6) 317 (26.8) 0.9069 
Current smoker 533 (36.0) 493 (41.7) 0.0027 
Dyslipidemia 884 (59.8) 720 (61.0) 0.5313 
Prior percutaneous coronary intervention 120 (8.1) 92 (7.8) 0.7595 
Prior stroke 58 (3.9) 50 (4.2) 0.6853 
Clinical presentation   <0.0001 
Unstable angina 581 (39.3) 198 (16.8)  
Non–ST-elevation myocardial infarction 562 (38.0) 339 (28.7)  
ST-elevation myocardial infarction 336 (22.7) 644 (54.5)  
Laboratory findings at admission    
White blood count, ×103/mL 8.8 ± 3.5 10.0 ± 3.5 <0.0001 
Hemoglobin, g/dL 14.3 ± 1.7 14.3 ± 1.8 0.7138 
Platelets, ×103/mL 243 ± 69 241 ± 64 0.3909 
Estimated glomerular filtration rate, mL/min/1.73 m2 78.8 ± 20.8 75.3 ± 26.6 0.0002 
<60 mL/min/1.73 m2 257 (17.4) 270 (22.9) 0.0004 
Antithrombotic drug before intervention    
Unfractionated heparin 923 (62.4) 737 (62.4) 0.9990 
Low–molecular-weight heparin 113 (7.6) 128 (10.8) 0.0043 
Glycoprotein IIb/IIIa inhibitors 95 (6.4) 84 (7.1) 0.4807 
Multivessel coronary artery disease 801 (54.2) 676 (57.2) 0.1121 
Percutaneous coronary intervention    
Emergent intervention 344 (23.3) 594 (50.3) <0.0001 
Multilesion intervention 282 (19.1) 245 (20.8) 0.2806 
Multivessel intervention 247 (16.7) 197 (16.7) 0.9892 
Treated lesions per patient 1.2 ± 0.5 1.2 ± 0.5 0.1734 
Total No. of stents per patient 1.3 ± 0.6 1.4 ± 0.7 0.0440 
Total stent length per patient, mm 34 ± 20 36 ± 20 0.0370 
3-month aspirin therapy 734 (49.6) 605 (51.2) 0.4123 
Data are presented as n ± standard deviation or n (percentage) 
 
 
Figure S1. Receiver operating characteristic curve analyses for major bleeding.  
 
 
Line indicates weight; dotted line, hemoglobin; dot, Youden's index. AUC, area under the curve. 
